Vaxcyte Inc reports results for the quarter ended June 30 - Earnings Summary

• Vaxcyte Inc PCVX.OQ reported a quarterly adjusted loss of $1.22​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $-1.10. The mean expectation of eight analysts for the quarter was for a loss of $1.17 per share. Wall Street expected results to range from $-1.31 to $-1.01 per share.

• Reported revenue was zero​; analysts expected zero.

• Vaxcyte Inc's reported EPS for the quarter was a loss of $1.22​.

• The company reported a quarterly loss of $166.57 million.

• Vaxcyte Inc shares had risen by 3.8% this quarter and lost 58.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Vaxcyte Inc is $141.50, about 76.2% above its last closing price of $33.73

This summary was machine generated from LSEG data August 6 at 09:25 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)